6 completed, 3 terminated, 2 recruiting. 6 Phase 3, 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 3, Terminated 2, Recruiting 1 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Milestone Pharmaceuticals Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 Placebo, Etripamil - Atrial Fibrillation | Phase 3 | Recruiting | Milestone Pharmaceuticals Inc. | 750 | 2026-08-20 | 2026-10-07 |
| The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients) Etripamil NS - Paroxysmal Supraventricular Tachycardia | Phase 2 | Recruiting | Milestone Pharmaceuticals Inc. | 60 | 2023-12-11 | 2026-07-21 |
| A Study of Etripamil in Healthy Subjects Etripamil Nasal Spray 70mg, Placebo - Healthy Chinese Subjects | Phase 1 | Completed | Corxel Pharmaceuticals | 12 | 2023-03-07 | 2023-04-10 |
| Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia Etripamil NS 70 mg, Placebo - Tachycardia, Supraventricular, Paroxysmal Supraventricular Tachycardia | Phase 3 | Completed | Corxel Pharmaceuticals | 500 | 2022-06-30 | 2026-10-22 |
| Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia Etripamil NS 70 mg, Aptar Pharma Nasal Spray Bidose System - Paroxysmal Supraventricular Tachycardia | Phase 3 | Completed | Milestone Pharmaceuticals Inc. | 130 | 2021-12-13 | 2026-05-15 |
| ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2 Etripamil, Placebo - Atrial Fibrillation | Phase 2 | Completed | Milestone Pharmaceuticals Inc. | 69 | 2020-11-19 | 2024-09-19 |
| Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303 Etripamil NS - Paroxysmal Supraventricular Tachycardia | Phase 3 | Completed | Milestone Pharmaceuticals Inc. | 1116 | 2019-09-23 | 2024-05-23 |
| Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302 Etripamil NS 70 mg, Aptar Pharma Nasal Spray Bidose System - Paroxysmal Supraventricular Tachycardia | Phase 3 | Terminated | Milestone Pharmaceuticals Inc. | 169 | 2018-12-10 | 2024-11-05 |
| Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT). Etripamil, Placebo, Etripamil Test Dose - Paroxysmal Supraventricular Tachycardia | Phase 3 | Terminated | Milestone Pharmaceuticals Inc. | 1097 | 2018-06-18 | 2024-07-12 |
| The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry. Paroxysmal Supraventricular Tachycardia (PSVT) | Terminated | Milestone Pharmaceuticals Inc. | 354 | 2017-10-16 | 2020-12-03 | |
| Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm Etripamil, Placebo - Paroxysmal Supraventricular Tachycardia (PSVT) | Phase 2 | Completed | Milestone Pharmaceuticals Inc. | 199 | 2015-03-27 | 2020-12-30 |
Tachycardia, Ventricular (9) · Atrial Fibrillation (2) · Tachycardia (2) · Tachycardia, Atrioventricular Nodal Reentry (2) · Tachycardia, Supraventricular (2)
etripamil (4)
Canada (8) · United States (8) · Netherlands (3) · China (2) · Germany (2) · Spain (2) · Argentina (1) · Belgium (1) · Brazil (1) · Colombia (1) · France (1) · Hungary (1) · Poland (1)
David Bharucha, MD (2) · Changsheng Ma (1) · Denis Roy, M.D (1) · Douglas Wight (1) · Francis Plat (1) · Francis Plat, MD (1) · James E. Ip, MD (1) · Lihang QI (1) · Xiaowen Chen (1) · Yuewen XI (1)
PMID 30049309, PMID 35728658, PMID 36441560, PMID 37331368, PMID 37753718, PMID 37950726, PMID 40931676, PMID 41668514
2018 (1)